Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    22056247 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Conditions: Renal Cell Carcinoma;   Nonclear Cell;   Temsirolimus Resistance
Intervention: Drug: Axitinib
2 Active, not recruiting
Has Results
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736);   Drug: Sorafenib

Indicates status has not been verified in more than two years